BBI News and Press, Brickell Biotech Inc. From 07/06/22

BOULDER, Colo., July 06, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics...

Brickell Biotech ( NASDAQ: BBI ) has announced that at the Co.’s stockholders approved a reverse stock split of the Co.'s common stock at a ratio between 1-to-10 and 1-to-45 and will become effective on July 5, 2022. The Co.'s common stock will begin trading on a sp...

BOULDER, Colo., July 01, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Amid the market turmoil we’ve seen this year, a number of companies have seen incredible downside pressure. Such is the case for  Brickell Biotech  (NASDAQ: BBI ). As of yesterday, BBI stock was tr...

Gainers: Allena Pharmaceuticals ( ALNA ) +191% . Brickell Biotech ( BBI ) +78% . Decibel Therapeutics ( DBTX ) +35% . Cognition Therapeutics ( CGTX ) +26% . Akouos ( AKUS ) +20% . Fujian Blue Hat Interactive Entertainment Tec...

The GDP report is out, and not much has changed in the overall stock market after yesterday’s sell-off. The S&P 500 (NYSEARCA: SPY ) closed at $380.65, and following the GDP report, the SPY sits within 20 cents of that figure. Whether or not there is a rebound in the stock ma...

You can’t argue that biotech stocks were hit hard during the 2022 stock market crash. But that doesn’t mean opportunity was utterly stifled. Depending on your outlook and investment style, volatility has become a considerable asset to some. You know what I’m talking abo...

Brickell Biotech (NASDAQ:BBI) said the first patients were dosed in the single ascending dose (SAD) portion of a phase 1 trial of BBI-02 capsules in healthy adults and patients with atopic dermatitis (AD), also known as eczema. "We are excited to announce initiation of the BBI-02-101 stu...

– BBI-02 is a potential first-in-class, oral DYRK1A inhibitor with strong preclinical validation and broad potential to treat debilitating autoimmune and inflammatory diseases – – Topline results from the SAD and MAD parts of the Phase 1 study expected to be...

NEW YORK, May 17, 2022 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEOs of: Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA), Brickell Biotech (NASDAQ: BBI), Idera Pharmaceuticals (...